Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 691-702

  Smits, Kim M ^a   Smits, Luc J M ^a   Schouten, Jan S A G ^a   Peeters, Frenk P M L ^a   Prins, Martin H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DECISION ANALYTIC MODEL; DIAGNOSTIC VALUE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDICATION; EVALUATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR DEPRESSION; NETHERLANDS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRESCRIPTION; PROBABILITY; REMISSION; SENSITIVITY ANALYSIS; THEORETICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; ECONOMICS, PHARMACEUTICAL; HUMANS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 34347356421     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.018     Document Type: Article

References (31)

1. Lesch K.P. Variation of serotonergic gene expression: Neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol 11 (2001) 457-474
2. Smits K.M., Smits L.J., Schouten J.S., et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 9 (2004) 433-441
3. Steimer W., Muller B., Leucht S., and Kissling W. Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta. 308 (2001) 33-41
4. Panzer P.E., Regan T.S., Chiao E., and Sarnes M.W. Implications of an SSRI generic step therapy pharmacy benefit design: An economic model in anxiety disorders. Am J Manag Care. 11 Suppl 12 (2005) S370-S379
5. Masand P.S. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 25 (2003) 2289-2304
6. Sheehan D.V., Eaddy M.T., Shah M.B., and Mauch R.P. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care. 11 Suppl 12 (2005) S354-S361
7. Arias B., Catalan R., Gasto C., et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-week follow up study. J Clin Psychopharmacol. 23 (2003) 563-567
8. Zanardi R., Serretti A., Rossini D., et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 50 (2001) 323-330
9. Zanardi R., Benedetti F., Di Bella D., et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 20 (2000) 105-107
10. Ito K., Yoshida K., Sato K., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 111 (2002) 235-239
11. Kim D.K., Lim S.W., Lee S., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11 (2000) 215-219
12. Lotrich F.E., and Pollock B.G. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet. 14 (2004) 121-129
13. Lotrich F.E., Pollock B.G., and Ferrell R.E. Polymorphism of the serotonin transporter: Implications for the use of selective serotonin reuptake in hibitors. Am J Pharmacogenomics 1 (2001) 153-164
14. Pollock B.G., Ferrell R.E., Mulsant B.H., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 23 (2000) 587-590
15. Rausch J.L., Johnson M.E., Fei Y.J., et al. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 51 (2002) 723-732
16. Smeraldi E., Zanardi R., Benedetti F., et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 3 (1998) 508-511
17. Yoshida K., Ito K., Sato K., et al. Influence of the serotonin transporter gene-linked polymorphic re gion on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 26 (2002) 383-386
18. Yu Y.W., Tsai S.J., Chen T.J., et al. Association study of the serotonin transporter promoter polymor phism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7 (2002) 1115-1119
19. Romeijnders A.C., van Marwijk H.W., Goudswaard A.N., and Nederlands Huisartsen Genootschap. Summary of the practice guideline 'depressive disorder' (first revision) from the Dutch College of General Practitioners [in Dutch]. Ned Tijdschr Geneeskd. 149 (2005) 523-527
20. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depres sive disorders: A systematic review. Lancet 361 (2003) 653-661
21. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of ef ficacy and tolerability. J Affect Disord. 58 (2000) 19-36
22. Mulrow C.D., Williams Jr. J.W., Chiquette E., et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 108 (2000) 54-64
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (1994), American Psychiatric Association, Washington, DC
24. Freemantle N., Anderson I.M., and Young P. Predictive value of pharmacological activity for the relative efficacy of anti depressant drugs. Meta-regression analysis. Br J Psychiatry 177 (2000) 292-302
25. Posternak M.A., and Miller I. Untreated short-term course of major depression: A meta-analysis of outcomes from studies using wait-list control groups. J Affect Disord. 66 (2001) 139-146
26. Serretti A., Benedetti F., Zanardi R., and Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1074-1084
27. Zimmerman M., Posternak M., Friedman M., et al. Which factors influence psychiatrists' selection of anti depressants?. Am J Psychiatry 161 (2004) 1285-1289
28. Steffens D.C., Krishnan K.R., and Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. Depress Anxiety. 6 (1997) 10-18
29. Dardennes R., Berdeaux G., Lafuma A., and Fagnani F. Comparison of the costeffectiveness of milnacipran (a SNRI) with TCAs and SSRls: A modeling approach. Eur Psychiatry 14 (1999) 152-162
30. Stewart A. Choosing an antidepressant: Effectiveness based pharmacoeconomics. J Affect Disord. 48 (1998) 125-133
31. Lenox-Smith A., Conway P., and Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmaco Economics 22 (2004) 311-319